+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Body mass repletion during ganciclovir treatment of cytomegalovirus infections in patients with acquired immunodeficiency syndrome



Body mass repletion during ganciclovir treatment of cytomegalovirus infections in patients with acquired immunodeficiency syndrome



Archives of Internal Medicine 149(4): 901-905



Disseminated cytomegalovirus (CMV) infection is a common complication of acquired immunodeficiency syndrome and contributes significantly to its morbidity and mortality. Ganciclovir, a guanosine analogue, inhibits CMV replication in vitro and in vivo, and its use can stabilize the clinical course of an affected patient. We examined the changes in body composition that occurred in four untreated patients and in eight patients who were treated with ganciclovir for serious CMV infections. Untreated patients lost weight, depleted body cell mass, as determined from total-body potassium measurements in a whole-body counter, lost body fat, as estimated from anthropometric measurements, and had a progressive fall in serum albumin concentration. In contrast, treated patients gained weight, repleted body cell mass and body fat, and increased serum albumin concentration during a three-month follow-up. In this study, it was estimated that ganciclovir therapy resulted in a net energy conservation of 2629 kJ/d. The ability to promote body cell mass repletion may be considered a demonstration of the efficacy of ganciclovir in the treatment of serious CMV infections in patients with acquired immunodeficiency syndrome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 007066666

Download citation: RISBibTeXText

PMID: 2539791

DOI: 10.1001/archinte.1989.00390040105021


Related references

Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. American Journal of Gastroenterology 88(4): 542-548, 1993

The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. American Journal of Ophthalmology 131(4): 457-467, 2001

Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. American Journal of Clinical Nutrition 53(1): 149-154, 1991

Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Archives of Ophthalmology 111(10): 1359-1366, 1993

Treatment of cytomegalovirus enterocolitis with ganciclovir in an infant with acquired immunodeficiency syndrome. Pediatric Infectious Disease Journal 7(5): 354-357, 1988

Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study. Antimicrobial Agents and ChemoTherapy 34(1): 176-178, 1990

Treatment of cytomegalovirus retinitis in acquired immunodeficiency syndrome with intravitreal ganciclovir implant. Journal of the Medical Association of Thailand 84(Suppl. 1): S142-S147, 2001

Treatment of disseminated cytomegalovirus infection with ganciclovir in a patient with acquired immunodeficiency syndrome. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 78(5): 686-687, 1989

Combined treatment with ganciclovir and foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Rinsho Ganka 52(5): 803-806, 1998

Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Pharmacy World and Science 15(2): 56-67, 1993

Sustained-release intravitreal ganciclovir pellets in the treatment of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. Australian and new Zealand Journal of Ophthalmology 23(2): 157-158, 1995

9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Annals of Internal Medicine 107(2): 133-137, 1987

Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. Journal of Infectious Diseases 183(2): 333-337, 2001

Progression rates of cytomegalovirus retinopathy in ganciclovir treated and untreated patients with acquired immunodeficiency syndrome. Investigative Ophthalmology & Visual Science 31(4 ABSTR ISSUE): 366, 1990

Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group report number 8. American Journal of Ophthalmology 132(5): 700-710, 2001